Features
The landscape of clinical trials has been transformed in a post-pandemic world. The first edition of the ISPE GAMP® Good Practice Guide: Validation and Compliance of...
Martin Heitmann
D-fine GmbH
Senior Manager
Martin Heitmann is a Senior Manager at d-fine. In this role, he transfers process design, data science, and large-scale implementation expertise into ambitious digital transformation projects. His first projects were in the financial industry, where he designed large data pools to apply predictive analytics for rating assessments. As d-fine expanded its operations to other industries, Martin took part in founding the d-fine healthcare unit. In the collaborative pharmaceutical community, Martin is an active member in various knowledge-sharing platforms and leads the ISPE GAMP® Global GxP-Compliant Use of AI Special Interest Group. He holds a Master of Science in business mathematics from the University of Mannheim. He has been a member of ISPE since 2022.
Related Articles
Features
Stakeholders across industries are becoming accustomed to using information technology (IT) systems, applications, and business solutions that feature artificial intelligence (AI) and machine learning (ML). Even though some of these uses show phenomenal performance, thorough risk management is required to ensure quality and regulatory compliance are met within the life sciences industry. By...
Technical
ChatGPT and other large language models are positioned to change the world. They can also shift acceptance and prevalence of machine learning solutions in regulated industries in general. However, their arrival requires reconsiderations on risks, quality assurance, and validation from a GxP perspective.
Features
Recent advances in artificial intelligence (AI) have led to its widespread industrial adoption, with machine learning (ML) algorithms demonstrating advances in performance in a wide range of tasks. However, this comes with an ever-increasing complexity of the algorithms used, rendering such systems more difficult to explain.
Technical
Artificial intelligence (AI) has the potential to benefit the pharmaceutical industry and its GxP-regulated areas. Several pharmaceutical companies are currently running digital pilots; 90% of large pharmaceutical companies have initiated AI projects.